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Introduction
Juvenile systemic sclerosis (jSSc) is a rare disease. We
developed a prospective assessment protocol for disease
involvement manifestations and progression of jSSc.
Objectives
To learn about the evolution of organ involvement, the
reliability of proposed assessment tools to measure
change in organ involvement, and the outcome of
patients in an early jSSc cohort.
Methods
Early jSSc patients, enrolled within 18 months after the
first non-Raynaud symptom of the disease, will be fol-
lowed over 36 months using a standardized assessment
protocol. No specific therapy will be suggested. An Inter-
net platform was created to make the project accessible:
http://www.juvenile-scleroderma.com. Interested col-
leagues can request the protocol, assessment tools, and a
model consent form to apply for local IRB approval. After
they receive local IRB approval, they will receive an access
code to the internal side of the homepage, where the
detailed protocol of the project and the assessment sheets
for the visits in PDF format are available. Data entry of the
patients is de-identified. The data will be summarized
every 6 to 12 months and presented at rheumatology
meetings. The principal investigator of each center will be
listed as co-author according to the number of enrolled
patients. Every 12 months the assessment tools will be
evaluated, with the help of a biostatistician, according the
OMERACT criteria.
Conclusion
This project will represent the first prospectively followed
cohort of jSSc patients, and will enable us to learn about
evolution disease and about the reliability of the pro-
posed assessment tools.
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